The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Eligibility for Intravenous Recombinant Tissue-Type Plasminogen Activator Within a Population: The Effect of the European Cooperative Acute Stroke Study (ECASS) III Trial
Open accessAbstract
Background and Purpose—: The publication of the European Cooperative Acute Stroke Study (ECASS III) expanded the treatment time to thrombolysis for acute ischemic stroke from 3 to 4.5 hours from symptom onset. The impact of the expanded time window on treatment rates has not been comprehensively evaluated in a population-based study. Methods—: All patients with an ischemic stroke presenting to an emergency department during calendar year 2005 in the 17 hospitals that compromise the large 1.3 million Greater Cincinnati/Northern Kentucky population were included in the analysis. Criteria for exclusion from thrombolytic therapy are analyzed retrospectively for both the standard and expanded timeframes with varying door-to-needle times. Results—: During the study period, 1838 ischemic strokes presenting to an emergency department were identified. A small proportion of them arrived in the expanded time window (3.4%) compared with the standard time window (22%). Only 0.5% of those who arrived in this timeframe met eligibility criteria for thrombolysis compared with 5.9% using standard eligibility criteria in the standard timeframe. These results did not vary significantly by repeated analysis varying the door-to-needle time or the expanded time window's exclusion criteria. Conclusions—: In reality, the expanded time window for thrombolysis in acute ischemic stroke benefits few patients. If we are to improve recombinant tissue-type plasminogen activator administration rates, our focus should be on improving stroke awareness, transport to facilities with ability to administer thrombolysis, and familiarity of physicians with acute stroke treatment guidelines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tissue Plasminogen Activator for Acute Ischemic Stroke
(1995) · New England Journal of Medicine · doi:10.1056/nejm199512143332401 · Cited by 11,654
Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke
Hacke, W., Kaste, M., Bluhmki, E., Brozman, M., Dávalos, A., Guidetti, D., Larrue, V., Lees, K. R., Medeghri, Z., Machnig, T., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804656 · Cited by 6,684
Lansberg, M. G., Schrooten, M., Bluhmki, E., Thijs, V. N., & Saver, J. L. (2009) · Stroke · doi:10.1161/strokeaha.108.540708 · Cited by 220
Cited by
Management of Acute Ischemic Stroke
Herpich, F., & Rincon, F. (2020) · Critical Care Medicine · doi:10.1097/ccm.0000000000004597 · Cited by 933
Demaerschalk, B. M., Kleindorfer, D. O., Adeoye, O. M., Demchuk, A. M., Fugate, J. E., Grotta, J. C., Khalessi, A. A., Levy, E. I., Palesch, Y. Y., Prabhakaran, S., et al. (2016) · Stroke · doi:10.1161/str.0000000000000086 · Cited by 670
Self-citationEndovascular Thrombectomy for Acute Ischemic Stroke: A Meta-analysis
Badhiwala, J. H., Nassiri, F., Alhazzani, W., Selim, M. H., Farrokhyar, F., Spears, J., Kulkarni, A. V., Singh, S., Alqahtani, A., Rochwerg, B., et al. (2015) · JAMA · doi:10.1001/jama.2015.13767 · Cited by 461
Stroke Thrombolysis: Save a Minute, Save a Day
Meretoja, A., Keshtkaran, M., Saver, J. L., Tatlisumak, T., Parsons, M. W., Kaste, M., Davis, S. M., Donnan, G. A., & Churilov, L. (2014) · Stroke · doi:10.1161/strokeaha.113.002910 · Cited by 366
Thrombo-inflammation in acute ischaemic stroke — implications for treatment
Stoll, G., & Nieswandt, B. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0221-1 · Cited by 332
Metadata
- Authors
- de los Ríos la Rosa, F., Khoury, J., Kissela, B. M., Flaherty, M. L., Alwell, K., Moomaw, C. J., Khatri, P., Adeoye, O., Woo, D., Ferioli, S., & Kleindorfer, D. O.
- Venue
- Stroke
- Published
- 2012-06
- Volume
- 43
- Issue
- 6
- Pages
- 1591-1595
- ISSN
- 0039-2499 (ISSN-L)
- 1524-4628
- OpenAlex
- W2111519145
- Cited by
- 165
- References
- 3
- FWCI
- 11.20
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Eligibility for Intravenous Recombinant Tissue-Type Plasminogen Activator Within a Population: The Effect of the European Cooperative Acute Stroke Study (ECASS) III Trial. https://app.cochat.ai/papers/10.1161/strokeaha.111.645986
- The paper
- de los Ríos la Rosa, F., Khoury, J., Kissela, B. M., Flaherty, M. L., Alwell, K., Moomaw, C. J., Khatri, P., Adeoye, O., Woo, D., Ferioli, S., & Kleindorfer, D. O. (2012). Eligibility for Intravenous Recombinant Tissue-Type Plasminogen Activator Within a Population: The Effect of the European Cooperative Acute Stroke Study (ECASS) III Trial. Stroke. https://doi.org/10.1161/strokeaha.111.645986
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.